Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jul 1:17:4187-4197.
doi: 10.2147/JIR.S453245. eCollection 2024.

PGM5-AS1 Promotes Progression of Diffuse Large B-Cell Lymphoma and Immune Escape by Regulating miR-503-5p

Xiaorong Qin  1 , Hongyan Li  1 , Jianqiu Wu  1 , Weiyan Tang  1 , Wenjuan Li  1 , Kejin Li  1
Affiliations

PGM5-AS1 Promotes Progression of Diffuse Large B-Cell Lymphoma and Immune Escape by Regulating miR-503-5p

Xiaorong Qin et al. J Inflamm Res. .

Abstract

Purpose: Diffuse large B-cell lymphoma (DLBCL) is a prevalent malignant condition with a dismal prognosis. LncRNA PGM5 antisense RNA 1 (PGM5-AS1) appears to be intricately involved in the progression of DLBCL, yet the modulatory mechanism remains unclear. The purpose of this study was to explore the expression of lncRNA PGM5-AS1 in DLBCL and its effect on the disease progression of DLBCL, as well as to explore its mechanisms.

Patients and methods: A total of 35 patients were included in the study. The expression levels of PGM5-AS1 and miR-503-5p in DLBCL tumor tissues and cell lines were detected by RT-qPCR. Cell proliferation was assessed using CCK8. Apoptosis rate was determined by flow cytometry. Cell invasion was examined by transwell assays. The specific interaction between PGM5-AS1 and miR-503-5p was verified through dual luciferase reporter gene assays. The immune related factors were detected by ELASA kits. The CD8+ T cells cytotoxicity was evaluated by LDH cytotoxicity kit.

Results: In DLBCL tumor tissues and cells, upregulated PGM5-AS1 expression, downregulated miR-503-5p expression, and elevated PD-L1 expression were observed. PGM5-AS1 functioned as a regulator in controlling DLBCL cell proliferation, apoptosis, and invasion by downregulating miR-503-5p expression. When CD8+ T cells were co-cultured with cells transfected with si-PGM5-AS1, the secretion of immunoregulatory factors increased, and the cytotoxicity of CD8+ T cells increased. These effects were mitigated by miR-503-5p inhibitors.

Conclusion: PGM5-AS1 accelerated DLBCL development and facilitated tumor immune escape through the miR-503-5p. Our discoveries offered an insight into lncRNA PGM5-AS1 serving as a prospective therapeutic target for DLBCL.

Keywords: DLBCL; PGM5-AS1; immune escape; miR-503-5p.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
PGM5-AS1 and miR-503-5p were differently expressed in DLBCL tissues and cells. (A and B) The levels of PGM5-AS1 and miR-503-5p in DLBCL tumor tissues (n=35) were detected by RT-qPCR (C) Pearson correlation analysis between PGM5-AS1 and miR-503-5p. (D and E) The levels of PGM5-AS1 and miR-503-5p in DLBCL cell lines were detected by RT-qPCR.
Figure 2
Figure 2
Downregulating PGM5-AS1 resulted in variations in cell proliferation, apoptosis, and invasion capabilities of DLBCL cells. (A) The levels of PGM5-AS1 in DLBCL cells were verified by RT-qPCR. (B and C) Viability of DLBCL cells was assessed by CCK-8. (D and E) Apoptosis in DLBCL cells was quantified by flow cytometry. (F and G) The invasion capability of DLBCL cells was assessed by the transwell assay.
Figure 3
Figure 3
Inhibition of miR-503-5p resulted in variations in cell proliferation, apoptosis, and invasion capabilities of DLBCL cell lines. (A) The levels of miR-503-5p in OCI-LY-7 and OCI-LY-10 cells were verified by RT-qPCR. (B and C) Viability of DLBCL cells was assessed by CCK-8. (D and E) Apoptosis in DLBCL cells was quantified by flow cytometry. (F and G) The invasion capability of DLBCL cells was assessed by the transwell assay. *P<0.05, **P<0.01, ***P<0.001.
Figure 4
Figure 4
PGM5-AS1 functions as a miR-503-5p sponge. (A) The binding site sequence between PGM5-AS1 and miR-503-5p was forecasted utilizing the lncRNASNP2 database. (B and C) The specific interaction between PGM5-AS1 and miR-503-5p was investigated using a dual luciferase reporter gene assay.
Figure 5
Figure 5
MiR-503-5p inhibitor reversed the effects on proliferation, apoptosis and invasion induced by si-PGM5-AS1. (A) The levels of miR-503-5p were assessed by RT-qPCR after si-PGM5-AS1 and miR-503-5p inhibitor treatment. (B and C) Cell proliferation was assessed using the CCK8 assay at intervals of 0, 24, 48, and 72 hours following si-PGM5-AS1 and miR-503-5p inhibitor administration. (D and E) Apoptosis in DLBCL cells was quantified by the Annexin V/PI assay. (F and G) The invasion capability of DLBCL cells was assessed by the transwell assay.
Figure 6
Figure 6
PGM5-AS1 exerts a regulatory influence on PD-L1 expression, IFN-γ and TNF-α secretion, and CD8+ T cell cytotoxicity by targeting miR-503-5p. CD8+ T cells were co-cultured with OCI-Ly7 and OCI-Ly10 cells with si-PGM5-AS1 and miR-503-5p inhibitor treatment. (A and B) The PD-L1 levels in DLBCL tumor tissues (n=35) and cell lines were detected by RT-qPCR. (C and D) Pearson correlation analysis between PGM5-AS1 and PD-L1, miR-503-5p and PD-L1. (E) PD-L1 levels were assessed by RT-qPCR after si-PGM5-AS1 and miR-503-5p inhibitor treatment. (F and G) Concentrations of TNF-α and IFN-γ were determined via ELISA kit. (H) The CD8+ T cells cytotoxicity was assessed using the LDH cytotoxicity assay kit.
See this image and copyright information in PMC

References

    1. Dunleavy K, Erdmann T, Lenz G. Targeting the B-cell receptor pathway in diffuse large B-cell lymphoma. Cancer Treat Rev. 2018;65:41–46. doi:10.1016/j.ctrv.2018.01.002 - DOI - PubMed
    1. Li S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018;50(1):74–87. doi:10.1016/j.pathol.2017.09.006 - DOI - PubMed
    1. Yuan J, Yang J, Wang R, Hao H, Li J. LncRNA NEAT1 regulate diffuse large B-cell lymphoma by targeting miR-495-3p/PD-L1 axis. Immuno Immunotoxicol. 2022;44(3):429–436. doi:10.1080/08923973.2022.2052896 - DOI - PubMed
    1. Zhu H, Yu J, Zhu H, Guo Y, Feng S. Identification of key lncRNAs in colorectal cancer progression based on associated protein-protein interaction analysis. World J Surg Oncol. 2017;15(1):153. doi:10.1186/s12957-017-1211-7 - DOI - PMC - PubMed
    1. Liang Y, Zhu H, Chen J, Lin W, Li B, Guo Y. Construction of relapse-related lncRNA-mediated ceRNA networks in Hodgkin lymphoma. Arch Med Sci. 2020;16(6):1411–1418. doi:10.5114/aoms.2020.98839 - DOI - PMC - PubMed

LinkOut - more resources